Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Innovation

T cell therapies promise life-changing outcomes for cancer patients, but their personalized, patient-specific nature throws a wrench into the classic centralized manufacturing playbook.

Innovation

Cell and gene therapies represent a revolutionary advance in personalized medicine, offering hope where traditional biologics and small molecules have struggled.

Bioprocessing

Getting an NDA signed shouldn’t feel like waiting for FDA approval. If your CRO needs weeks just to kickstart paperwork…

Bioprocessing

When drug safety fails, patients—and entire markets—pay the price. Understanding your CMC isn’t just compliance; it’s the line between therapeutic promise and product recall.

Bioprocessing

What’s the real difference between a shake flask, a microtiter plate, and a full-scale bioreactor—and why do so many experiments go sideways, even when the SOP looks perfect?

Bioprocessing

In bioprocess development, orbital-shaken bioreactors—shake flasks, spin tubes, and microtiter plates—are the unsung backbone powering industry decisions about production strains and media.

Bioprocessing

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy’s success.

Bioprocessing

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?

Bioprocessing

Is your process model gathering dust while real-world decisions march on without it?

Bioprocessing

Bioprocess development lies at the heart of modern biotechnology, turning innovative molecules into life-changing therapies.

Bioprocessing

Bioreactor scale-up failures are still one of the top reasons promising cell therapies never reach the clinic. Traditional “power per volume” scale-up is often just a best guess—putting product quality and timelines at risk.

Bioprocessing

Can computational fluid dynamics (CFD) join the ranks of everyday tools in bioprocess engineering—right alongside spreadsheets and pH meters?

Data & Analytics

How do you actually measure and shrink your true environmental impact, when most data is missing and every facility operates on a different baseline?

Data & Analytics

Is your manufacturing strategy bleeding money in ways you can’t see?

Data & Analytics

Biotechnology is often perceived as a field exclusively for those with a background in biology.

Data & Analytics

Bioprocess development has long been recognized for its complexity, requiring rigorous experimentation, considerable time, and substantial resources. Yet a shift is underway.

Data & Analytics

ELISA (Enzyme-linked Immunosorbent Assay) has been a workhorse in biotech laboratories for decades.

Biotech Success

You may have the next blockbuster molecule in your pipeline.

Biotech Success

Many bioproduction development projects fail due to inadequate stakeholder engagement.

Biotech Success

Lars Brandén has travelled an uncommon route from a youthful fascination with viruses to leading biology at Kolibri, a Paris-based company developing acoustic bioreactors and novel transfection chemistries.

Biotech Success

I want to let you in on a secret. Truly transformative bioprocess development is not just about creative brainstorming in the lab.

Biotech Success

Biomanufacturing has evolved from producing simple recombinant hormones to assembling highly complex biologics in living systems.

Biotech Success

Bringing a new therapeutic biologic from discovery to clinic is a delicate balancing act of cutting‑edge science, tight regulatory timelines, and rapid iteration. One misalignment—whether in documentation, communication, or data interpretation—can quickly derail months of hard work.

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Innovation

Cell and gene therapies rely on the fragile integrity of life itself—a single cell surviving through an unforgiving journey from lab to patient

Innovation

What if the breakthrough in AI-driven protein therapeutics hinges less on machine learning algorithms and more on a bold rethink of how companies share their most valuable resource—data?

Innovation

There’s a reason so many “picture-perfect” protein designs never make it past the computer screen: the leap from simulation to real-world function is wider than it looks.

Innovation

Is a future without heart attacks and strokes within reach—not just delayed, but truly reversed?

Innovation

What if the boldest therapeutic breakthroughs begin with questioning the very boxes we use to define drugs?

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.